Mihai-Liviu Ursachi, MD
Internal Medicine · Galion, OHNPI 1497747877
Payments from drug & device makers
Across 103 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$298
- Amgen$274
- AstraZeneca$264
- Lilly USA, LLC$132
- AbbVie$108
- Boehringer Ingelheim$103
- plus $699 from 20 others
What the payments were for
- Food & beverage$1,878100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $298 |
| Amgen | 9 | $274 |
| AstraZeneca | 15 | $264 |
| Lilly USA, LLC | 9 | $132 |
| AbbVie | 4 | $108 |
| Boehringer Ingelheim | 6 | $103 |
| Bayer | 6 | $94 |
| Abbott | 5 | $88 |
| Phathom Pharmaceuticals, Inc. | 4 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $67 |
| Novo Nordisk | 4 | $62 |
| Merck | 4 | $55 |
| Johnson & Johnson | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Viiv Healthcare Company | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$101
How this compares
$1,878 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 151 | $153,237 |
| TrulicityDulaglutide | 136 | $141,934 |
| EliquisApixaban | 124 | $117,788 |
| OzempicSemaglutide | 112 | $109,123 |
| MounjaroTirzepatide | 47 | $53,984 |
| Repatha SureclickEvolocumab | 75 | $52,842 |
| FarxigaDapagliflozin Propanediol | 64 | $39,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $39,368 |
| XareltoRivaroxaban | 37 | $38,313 |
| JanuviaSitagliptin Phosphate | 37 | $37,972 |
| CreonLipase/Protease/Amylase | 22 | $20,049 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $15,570 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 34 | $11,421 |
| EntrestoSacubitril/Valsartan | 12 | $10,935 |
| MyrbetriqMirabegron | 11 | $9,755 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25 | $132 | $197,709194 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $103 | $161,180167 claims |
| PfizerEliquis | $16 | $117,788124 claims |
| Novo NordiskOzempic | $62 | $109,123112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $264 | $55,38186 claims |
| Johnson & JohnsonXarelto | $39 | $38,31337 claims |
| MerckJanuvia | $55 | $37,97237 claims |
| AbbVieCreon | $108 | $20,04922 claims |
| NovartisEntresto | $298 | $10,93512 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $9,75511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Galion
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.